GCP II inhibition rescues neurons from gp120IIIB-induced neurotoxicity

Excessive glutamate neurotransmission has been implicated in neuronal injury in many disorders of the central nervous system (CNS), including human immunodeficiency virus (HIV)-associated dementia. Gp120IIIB is a strain of a HIV glycoprotein with specificity for the CXCR4 receptor that induces neuronal apoptosis in in vitro models of acquired immunodeficiency syndrome (AIDS)-induced neurodegeneration. Since the catabolism of the neuropeptide N-acetylaspartylglutamate (NAAG) by glutamate carboxypeptidase (GCP) II increases cellular glutamate, an event associated with excitotoxicity, we hypothesized that inhibition of GCP II may prevent gp120IIIB-induced cell death. Furthermore, through GCP II inhibition, increased NAAG may be neuroprotective via its agonist effects at the mGlu3 receptor. To ascertain the therapeutic potential of GCP II inhibitors, embryonic day 17 hippocampal cultures were exposed to gp120IIIB in the presence of a potent and highly selective GCP II inhibitor, 2-(phosphonomethyl)-pentanedioic acid (2-PMPA). 2-PMPA was found to abrogate gp120IIIB-induced toxicity in a dose-dependent manner. Additionally, 2-PMPA was neuroprotective when applied up to 2 h after the application of gp120IIIB. The abrogation of apoptosis by 2-PMPA was reversed with administration of mGlu3 receptor antagonists and with antibodies to transforming growth factor (TGF)-β. Further, consistent with the localization of GCP II, 2-PMPA failed to provide neuroprotection in the absence of glia. GCP II activity and its inhibition by 2-PMPA were confirmed in the hippocampal cultures using radiolabeled NAAG and high-performance liquid chromatography (HPLC) analysis. Taken together, these data suggest that GCP II is involved in mediating gp120-induced apoptosis in hippocampal neurons and GCP II inhibitors may have potential in the treatment of neuronal injury related to AIDS.

[1]  S. Lipton.  HIV-related neuronal injury , 1994, Molecular Neurobiology.

[2]  J. Neale,et al.  The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. , 2005, Trends in pharmacological sciences.

[3]  A. Maroney,et al.  Mixed lineage kinase 3 mediates gp120IIIB‐induced neurotoxicity , 2002, Journal of neurochemistry.

[4]  X. C. Lu,et al.  Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. , 2001, European journal of pharmacology.

[5]  Stuart A. Lipton,et al.  Pathways to neuronal injury and apoptosis in HIV-associated dementia , 2001, Nature.

[6]  J. Becker,et al.  HIV-associated neurologic disease incidence changes: , 2001, Neurology.

[7]  B. Slusher,et al.  N-Acetylated alpha-linked acidic dipeptidase converts N-acetylaspartylglutamate from a neuroprotectant to a neurotoxin. , 2000, The Journal of pharmacology and experimental therapeutics.

[8]  F. Tortella,et al.  Neuroprotection produced by the NAALADase inhibitor 2-PMPA in rat cerebellar neurons. , 2000, European journal of pharmacology.

[9]  I. Black,et al.  Glutamate carboxypeptidase II is expressed by astrocytes in the adult rat nervous system , 1999, The Journal of comparative neurology.

[10]  F. Tortella,et al.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury , 1999, Nature Medicine.

[11]  S. Nakanishi,et al.  Activation of the extracellular signal‐regulated kinase 2 by metabotropic glutamate receptors , 1999, The European journal of neuroscience.

[12]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[13]  R. Miller,et al.  Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  F. Nicoletti,et al.  Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells , 1998, Neuroscience.

[15]  K. Flanders,et al.  TRANSFORMING GROWTH FACTOR-βS IN NEURODEGENERATIVE DISEASE , 1998, Progress in Neurobiology.

[16]  K. Flanders,et al.  Transforming growth factor-betas in neurodegenerative disease. , 1998, Progress in neurobiology.

[17]  S. Lipton.  Neuronal injury associated with HIV-1: approaches to treatment. , 1998, Annual review of pharmacology and toxicology.

[18]  J. Meldolesi,et al.  HIV‐1 gp120 glycoprotein affects the astrocyte control of extracellular glutamate by both inhibiting the uptake and stimulating the release of the amino acid , 1997, FEBS letters.

[19]  J. Neale,et al.  N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells , 1997, Journal of neurochemistry.

[20]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[21]  O. Meucci,et al.  gp120-Induced Neurotoxicity in Hippocampal Pyramidal Neuron Cultures: Protective Action of TGF-β1 , 1996, The Journal of Neuroscience.

[22]  D. Budd,et al.  Presynaptic receptors and the control of glutamate exocytosis , 1996, Trends in Neurosciences.

[23]  L. E. Ross,et al.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. , 1996, Journal of medicinal chemistry.

[24]  D. Choi,et al.  The inhibitory mGluR agonist, s-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA neurotoxicity and oxygen-glucose deprivation-induced neuronal death , 1995, Neuropharmacology.

[25]  R. Duvoisin,et al.  The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.

[26]  P. Sindou,et al.  Prevention of HIV coat protein (gp120) toxicity in cortical cell cultures by riluzole , 1994, Journal of the Neurological Sciences.

[27]  H. Shinozaki,et al.  (2 S,1′ R,2′ R,3′ R)-2-(2,3-dicarboxycyclopropyl) glycine positively modulates metabotropic glutamate receptors coupled to polyphosphoinositide hydrolysis in rat hippocampal slices , 1994, Brain Research.

[28]  J. Neale,et al.  N-Acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia , 1993, Neuropeptides.

[29]  P. Conn,et al.  Activation of metabotropic glutamate receptors increases cAMP accumulation in hippocampus by potentiating responses to endogenous adenosine , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  S. Lipton,et al.  Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity , 1991, Neuron.

[31]  Richard J. Miller,et al.  Excitotoxicity induced by enhanced excitatory neurotransmission in cultured hippocampal pyramidal neurons , 1990, Neuron.

[32]  J. Coyle,et al.  The effects of N-acetylated alpha-linked acidic dipeptidase (NAALADase) inhibitors on [3H]NAAG catabolism in vivo , 1989, Neuroscience Letters.

[33]  J. Coyle,et al.  Hydrolysis of the Brain Dipeptide N‐Acetyl‐l‐Aspartyl‐l‐Glutamate: Subcellular and Regional Distribution, Ontogeny, and the Effect of Lesions on N‐Acetylated‐α‐Linked Acidic Dipeptidase Activity , 1988, Journal of neurochemistry.

[34]  J. Coyle,et al.  Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. , 1987, The Journal of biological chemistry.